U.S. Markets close in 2 hrs 35 mins

Varian Medical Systems, Inc. (VAR)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
175.48-0.22 (-0.13%)
As of 1:25PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close175.70
Open175.90
Bid175.54 x 800
Ask175.54 x 800
Day's Range175.40 - 175.99
52 Week Range89.62 - 176.50
Volume473,452
Avg. Volume712,121
Market Cap16.116B
Beta (5Y Monthly)1.06
PE Ratio (TTM)57.88
EPS (TTM)3.03
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 02, 1998
1y Target Est177.75
  • Varian Announces CEO Succession Plan
    PR Newswire

    Varian Announces CEO Succession Plan

    Varian (NYSE: VAR) today announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG (Frankfurt: SHL). Wilson will be succeeded by Chris Toth, President and Chief Operating Officer of Varian, who will become CEO of the Varian business segment of Siemens Healthineers upon the transaction close. Toth will report directly to Dr. Bernd Montag, Chief Executive Officer of Siemens Healthineers.

  • CTSI Oncology Solutions, a Varian Company, to Provide Technology-Enabled Services for Radiation Oncology at CHRISTUS Health
    PR Newswire

    CTSI Oncology Solutions, a Varian Company, to Provide Technology-Enabled Services for Radiation Oncology at CHRISTUS Health

    CTSI Oncology Solutions, a Varian (NYSE: VAR) company that provides oncology services for healthcare providers worldwide, has entered into a long-term, multi-year agreement with CHRISTUS Health, a Texas-based health system, to provide a broad spectrum of technology-enabled services in radiation oncology. Under the agreement, CTSI will provide six CHRISTUS radiation oncology departments with comprehensive support designed to increase efficiency, track and enhance quality, and reduce costs.

  • Varian Becomes First Medical Technology Company Joining the Cancer Drug Development Forum
    PR Newswire

    Varian Becomes First Medical Technology Company Joining the Cancer Drug Development Forum

    Varian (NYSE: VAR) announced it has joined the Cancer Drug Development Forum (CDDF) as an industry partner. This makes Varian the first medical technology company to join CDDF, the leading non-competitive drug development platform in Europe. CDDF's objective is to stimulate advancement in cancer drug development and access.